Latest News
Costco Holds Cash, Focuses on Digital Growth After Strong Quarter
Costco posted quarterly sales of $68.24 billion and net income of $2.04 billion, exceeding forecasts. The company holds $17.38 billion in cash but has no immediate plans for a special dividend, focusing instead on warehouse expansion and digital investments.
Jefferies Faces Legal Battle, Limits MFS Losses Under $20M
Jefferies Financial Group disclosed that losses from the collapse of UK lender Market Financial Solutions will likely remain below $20 million. The firm also contested a $126.4 million claim from Western Alliance Bancorporation, sparking a legal dispute.
Red Cat Shares Retreat After Pentagon Drone Shortlist, Q4 Revenue Surge Awaited
Red Cat Holdings shares declined approximately 4% Monday after its drone unit was named a finalist for Pentagon contracts, tempering a recent rally. The company anticipates reporting a massive year-over-year revenue increase for its fourth quarter on March 18.
Atara Biotherapeutics Surges on FDA Leadership Shift, EBVALLO Review in Focus
Atara Biotherapeutics shares surged 18% Monday following news of an upcoming FDA leadership change, reviving investor hope for a reconsideration of its rejected EBVALLO therapy for a rare blood cancer.
Capricor Shares Gain Ahead of Key Duchenne Data and Financial Update
Capricor Therapeutics shares advanced 7.6% as the company prepares to release quarterly results and full Phase 3 data for its Duchenne muscular dystrophy drug deramiocel on March 12.
Nasdaq, Kraken Forge Tokenized Stock Platform for 2027 Rollout
Nasdaq is developing a tokenized shares framework with crypto exchange Kraken, aiming to link traditional markets with blockchain networks by the first half of 2027.
Wealth Managers Boost QQQ Stakes, but Data Lags Market Moves
Recent SEC filings reveal two wealth managers raised their stakes in the Invesco QQQ ETF in Q3 2025, though subsequent data shows one trimmed its position by year-end. The Nasdaq-100 tracker traded near $593, down 1.1%, as investors weigh growth prospects against macro risks.
Servier Acquires Day One Biopharmaceuticals in $2.5 Billion Oncology Deal
French pharmaceutical firm Servier will acquire Day One Biopharmaceuticals for $2.5 billion, gaining the pediatric glioma treatment Ojemda. The deal offers a 68% premium to Day One's recent closing price.
Unusual Machines Shares Surge on Preliminary 2025 Revenue Doubling
Unusual Machines shares climbed 7% Monday following preliminary results showing 2025 revenue more than doubled to $11.2 million and cash reserves topped $103 million. The drone components maker also reported a widened quarterly operating loss.
W&T Offshore Posts Wider 2025 Loss Amid Revenue Drop, Sees Regulatory Relief
W&T Offshore disclosed a deeper net loss for 2025, with revenue declining to $501.5 million. The company highlighted reduced net debt and potential regulatory relief from proposed offshore financial assurance rules.
Reviva Pharma Enacts Reverse Split to Fend Off Nasdaq Delisting
Reviva Pharmaceuticals Holdings has implemented a 1-for-20 reverse stock split to boost its share price and avoid a Nasdaq delisting, with a critical compliance deadline of March 27. The company also faces financing challenges for an additional Phase 3 trial of its schizophrenia drug candidate, brilaroxazine.
uniQure Shares Soar on FDA Leadership Shift Amid Gene Therapy Dispute
uniQure shares jumped 34% in premarket trading following news that FDA biologics chief Vinay Prasad will depart in April. The move comes amid a regulatory standoff over the company's Huntington's disease gene therapy.